Lucas and Spampinato (2000) described our study as showing that ketanserin, a preferential serotonin 5-HT 2A antagonist, failed to modify the enhancement of striatal dopamine (DA) efflux induced by intrastriatal infusion of 1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane (DOI).
REPLY FROM DR. G. LUCAS AND DR. U. SPAMPINATO
To the Editors:
In their letter, Balcioglu and Wurtman state that their observations did not support the conclusion of that serotonin 5-HT 2A receptors are not involved in mediating the enhancement of dopamine (DA) release by 1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane (DOI). We do not agree with this statement. Indeed, as they point out in their letter, the preferential 5-HT 2A antagonist ketanserin reduced the basal release of DA to 27 Ϯ 5% of baseline by itself. Now, given that the facilitatory effect of DOI is "blocked" in the presence of ketanserin, one may suppose that extracellular levels of DA are close to baseline, in the vicinity of 100% of basal values, in rats receiving the combination of ketanserin and DOI. Thus, after pretreatment with ketanserin, it appears that DOI still induces approximately a threefold increase of DA release (reaching about 100% of baseline), compared to the condition with ketanserin alone (27%). This result is very similar to that observed when DOI is administered alone, that is, a 2.5-to threefold (256 Ϯ 90% of baseline) enhancement of DA release. In summary, because of the existence of this inhibitory effect of ketanserin on its own, we concluded that the data reported in the abstract from allow one to conclude that this latter drug does not block the effect of DOI. This interpretation of their data is therefore in agreement with our own findings, showing that the intrastriatal infusion of a selective 5-HT 2A antagonist has no influence on the increase of DA release induced by the perfusion of a low concentration (1 M) of DOI.
*Guillaume Lucas

